You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康希諾生物漲5%上海mRNA產業化基地首期規劃產能1億劑
格隆匯8月5日丨港股康希諾生物(6185.HK)漲5.16%,報64.15港元;A股康希諾(688185.SH)漲3.06%,報158.76元,總市值393億元。消息面上,康希諾正在上海臨港建設mRNA產業化基地,首期規劃產能為1億劑。公司提前佈局了可以激發粘膜免疫的吸入劑型的開發,同時也在探索二價疫苗的開發,不僅限於腺病毒載體技術平台,也在基於mRNA技術平台進行候選疫苗的開發。公司已開展接種三針滅活疫苗的人羣中序貫加強第四針腺病毒載體新冠疫苗的臨牀試驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account